Release Date: April 07, 2021
Expiration Date: April 07, 2022

Target Audience:

This activity has been designed to meet the educational needs of hepatologist and other healthcare providers involved in the care of patients with Progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss recent advances in genetic diagnostic panels for patients with rare pediatric cholestatic liver disease.
  • Review recent advances in the treatment of patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
  • Analyze current treatment strategies for patients with ALGS and PFIC, the need for emerging therapies and how they will fit into treatment strategies.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Chronic Liver Disease Foundation (CLDF). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by educational grants from Albireo Pharma, Inc. and Mirum Pharmaceuticals, Inc.

Accredited by

Provided by

DON'T MISS THIS CME WEBCAST!

0.75 AMA PRA Category 1 Credits™

AGENDA

Opening Remarks
Kris Kowdley, MD

Diagnosis Update
Tamir Miloh, MD

Treatment Update
Naim Alkhouri, MD

Closing Remarks
Kris Kowdley, MD

NAIM ALKHOURI, MD

VP of Academic Affairs
Chief of Transplant Hepatology
Director of the Fatty Liver and Metabolic Liver Diseases
Arizona Liver Health (ALH)
Glendale, Arizona

Naim Alkhouri, M.D., is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX.

Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.

Dr. Alkhouri has been published in over 160 publications and presents his work at both national and international medical conferences. Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease.

Dr. Alkhouri's specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation.

FACULTY DISCLOSURES

Research Funds: Albireo, Gilead, and Intercept
Honorarium: Gilead and Intercept.
Speaker Advisor/Investigator:Albireo, Gilead, and Intercept.

Kris Kowdley, MD

Liver Institute Northwest
Clinical Professor of Medicine
S. Floyd College of Medicine
Washington State University
Seattle, Washington

Dr. Kris Kowdley, Director of Liver Institute Northwest and clinical professor, Elson S. Floyd College of Medicine at Washington State University, received his B.S. in Biology and Anthropology as a member of the Dean's List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine. Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in liver disease. He has led several major international clinical trials of new treatments for hepatitis C, primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis. Dr. Kowdley's translational and laboratory research focuses on the role of iron as a co-factor in nonalcoholic steatohepatitis, novel murine models, and biomarkers for nonalcoholic steatohepatitis and primary sclerosing cholangitis. His research program has been continually funded by the National Institutes of Health since 1999.

Dr. Kowdley is the author of more than 500 articles, book chapters, reviews and commentaries, and his scholarly work has been cited more than 46,000 times (h-index 98), according to Google Scholar. He is on the Web of Science list of "Highly Cited Researchers" (top 1% by citations for field) for 2019 and 2020.

FACULTY DISCLOSURES

Honorarium: Genfit, GSK, Gilead, Intercept, and Mirum.
Speaker/Consultant: Genfit, Gilead, Intercept, and Mirum.
SPI of Trial: GSK

Tamir Miloh, MD

Professor of Pediatric
Medical Director, Pediatric Transplant Hepatology
Miami Transplant Institute
Miami, Florida

Tamir Miloh, M.D. is the Director of Pediatric Liver Transplant Medicine at Jackson Memorial. Dr Miloh is actively involved in clinical investigation of various pediatric liver diseases such as liver transplantation, primary sclerosing cholangitis (PSC), autoimmune hepatitis, Wilson's disease, metabolic diseases, biliary atresia, nonalcoholic fatty liver disease (NAFLD) and acute liver failure. He has a special interest in increasing children's access to transplant, improving patient's adherence and transition of care to adult providers. He completed a residency in Pediatrics at St Christopher's Hospital for Children, Philadelphia with subsequent fellowship training in Pediatric Gastroenterology, Hepatology and Liver Transplant at Mount Sinai Hospital, New York. After 5 years, he established a new pediatric liver transplant program at Phoenix Children's Hospital in collaboration with the Mayo clinic. He served as the Director of Pediatric Hepatology and Liver Transplant and was an Associate Professor at the University of Arizona and the Mayo clinic, until his recruitment to Texas Children's Hospital and the Baylor College of Medicine in 2015 as the director of pediatric hepatology and transplant and advanced pediatric hepatology fellowship. Dr. Miloh has been the primary investigator and co-investigator in numerous NIH, FDA and pharmacy initiated studies of children with chronic liver disease. He has leadership roles in United Network of Organ Sharing (UNOS), Studies of Pediatric Liver Transplantation (SPLIT), North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), American Association for the Study of Liver Disease (AASLD) and the Wilson's Disease Association.

FACULTY DISCLOSURES

Speaker Advisor/Reviewer: Alexion
Honorarium: Albireo, Alexion, and Mirum.